Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group
Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide with the Swiss public company Polypeptide Group. The new production, at a larger scale, will be essential for the clinical trial program in bladder cancer, currently advancing towards Phase III.Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the Polypeptide Group, a leading CDMO company in peptide synthesis. Through a cooperative effort with the